Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

All GLG News Analyses Filed Under: Business of Medicine

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Is the Controversy over the Public Option the biggest Red Herring Ever?

November 20, 2009

GLG Expert Contributor

Reid Pushes for Votes on Health-Care Bill | www.washingtonpost.com

Nothing has raised the hackles of partisan Democrats and especially Republicans more this year than the public health insurance option. On the left, liberals consider it to be the indispensable component of true healthcare reform. On the right, conservatives refer to it to the first step on the slippery slope to socialism, if not a return to the Third Reich this time in America. Yet, the truth is that its impact will likely be so small, its presence (or absence) hardly merits any debate.

Will Bundles of Healthcare Payments Bring Joy to Anybody?

November 13, 2009

GLG Expert Contributor

RAND: Bundled Payments the Best Way to Contain Healthcare Costs | www.fiercehealthcare.com

Analysts at RAND Corp. have thrown their weight behind the use of bundled fees to pay physicians and hospitals. They have concluded that although difficult to implement, doing so is probably the most effective way to contain health care costs which could spin even more out of control under the current health care reform proposals and ultimately bankrupt the federal government without dramatic changes to the current fee for service system.

Novartis, Sleeping Giant Wakes-Up in China

November 6, 2009

GLG Expert Contributor

Novartis to invest US$ 1 bn to build largest pharma R&D institute in China | www.pharmabiz.com

Novartis to grow its China presence, late.Novartis has a slow response to market opportunities.GlaxoSmithKline and other big pharma players are perhaps too large to compete in the world's changing markets.

Ken Powell, President

Ken PowellPresidentGenesis Business Development, LLC What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

FDA Publishes H1N1 Diagnostic Test Guidance

November 5, 2009

FDA Publishes Guidance Document for H1N1 Dx | www.genomeweb.com

The FDA published document designed to help diagnostic test manufactures develop H1N1 tests and data that would accompany a FDA application to market them.  This follows on the recent issuance of CDC guidelines for H1N1 tests.

What Will Help The Poor?

November 3, 2009

GLG Expert Contributor

Deficit Plays into Health Reform | www.washingtonpost.com

There is no doubt that a great deal of time, efforts and resources have gone into trying to find a solution to the healthcare problems and concerns that we deal with today. What is not as clear to those who really need these problems solved are the answers thus far. A lot of very smart people seem to have forgotten the actual value of a person. What ever numbers show up on the balance sheet hardly provides any direction to those who care more about dollars and cents than common sense.

Pharma Outsourcing: Where Will it End?

November 3, 2009

GLG Expert Contributor

Quintiles inks pharma deals | www.outsourcing-pharma.com

A major supplier of clinical development services has just been awarded all of Astra Zeneca's clinical pharmacology work. Such work was traditionally performed internally but is now one of many stages of development being outsourced. This follows similar trends in research, where pharma companies are forging external relationships. We question where the pharma industry is headed and how much of its core business will remain in-house.

ASTRO/ACRO help win the fight against Reimbursement Cuts for Radiation Oncology

November 2, 2009

GLG Expert Contributor

CMS announcement regarding Radiation Oncology Reimbursement for 2010 | cs.astro.org

Major news breaking.. CMS has decided to implement only a 1% cut annually for radiation oncology reimbursement.   This may be the most important news item in the world of oncology for the past decade.   Faced with untenable projected cut of 19%, CMS reversed course and reduced the reduction in payment.

It's Time for Health Care Reform--Not Just Health Insurance Reform!

October 30, 2009

GLG Expert Contributor

The Health Care Reform Debate We Need | blog.nj.com

With so much emphasis on changing the health insurance system, the far greater need to change the delivery and financing of care has gotten relatively little mention, at least in the sound bites where most people receiving their daily news. We should not squander this once in a lifetime change for real health care, and not just health insurance reform.

Shares That Go Bump In The Night

October 30, 2009

GLG Expert Contributor

Transcept Pharma sleep drug denied approval, shrs sink | www.reuters.com

Transcept is developing Intermezzo for Middle of Night Insomnia. Intermezzo is low dose zolpidem (same chemical as Ambien). FDA's questions delay access to the $7 billion US sleep disorder market. Transcept's shares dropped dramatically on the news

HIV/AIDS DRUG-INDUS BIOTECH

October 27, 2009

GLG Expert Contributor

Indus Biotech develops drug to control HIV/AIDS | www.pharmabiz.com

This is indeed great news for HIV sufferers all over the world. Since the drug is derived from botanical sources, the cost will be within the reach of millions in the developing world. It will also help those infected with HIV in the developed world where the cost of conventional therapies are extremely high.Ashok Bendre

Page : 12345678910Next1 to 10 of 1031

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Leading institutions connect with members of the Healthcare councils through GLG

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
7 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software